Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Milowsky, M.; Ramamurthy, C.; Mar, N.; McKay, R. R.; Friedlander, T.; Ferrario, C.; Bracarda, S.; George, S.; Moon, H.; Geynisman, D.; Petrylak, D. P.; Borchiellini, D.; Burgess, E. F.; Rey, J. P. M.; Carret, A. S.; Yu, Y.; Guseva, M. V.; Moreno, B. H.; O'Donnell, P. H. |
| Abstract Title: | Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1441 |
| Language: | English |
| ACCESSION: | WOS:000866211602489 |
| DOI: | 10.1016/j.annonc.2022.08.079 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA73 -- Source: Wos |
